Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
CV

NASDAQ · CV

CapsoVision, Inc.

Healthcare · Medical - Equipment & Services

$6.52

Up+$0.15 (+2.35%)

Updated Sep 11, 2026, 6:27 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
674.03M
P/E ratio
-28.7
Dividend yield
0.00%
52-week range
$4.74 – $9.17
Volume
163.62K
Avg. volume
80.82K

Price performance

CV price history

1M range · 20 trading sessions · Daily adjusted prices

CV closed at $6.52 after 20 trading sessions, down 3.98% for the selected period.

Last close
$6.52
Period change
-3.98%
Period low
$5.82
Period high
$6.79
Daily close
View OHLC price history
CV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$6.29$6.70$6.29$6.52163.62K
Sep 9, 2026$6.30$6.68$6.24$6.37185.25K
Sep 8, 2026$5.99$6.99$5.99$6.36391.4K
Sep 4, 2026$5.93$6.09$5.92$5.9938.5K
Sep 3, 2026$6.01$6.01$5.83$5.9762.72K
Sep 2, 2026$5.88$6.05$5.88$5.9358.64K
Sep 1, 2026$5.80$5.97$5.785$5.8762.22K
Aug 31, 2026$5.95$6.13$5.81$5.8458.77K
Aug 28, 2026$6.13$6.2837$5.93$5.9383.05K
Aug 27, 2026$5.80$6.115$5.75$6.0675.14K
Aug 26, 2026$5.88$5.92$5.77$5.8250.45K
Aug 25, 2026$5.89$6.00$5.785$5.8574.52K
Aug 24, 2026$6.05$6.18$5.82$5.8377.08K
Aug 21, 2026$5.95$6.14$5.86$6.0268.65K
Aug 20, 2026$6.12$6.255$5.895$5.91105.3K
Aug 19, 2026$6.17$6.3086$6.05$6.1291.71K
Aug 18, 2026$6.40$6.52$6.03$6.15150.82K
Aug 17, 2026$6.28$6.755$6.28$6.44569.21K
Aug 14, 2026$6.50$6.68$6.10$6.46151.84K
Aug 13, 2026$6.91$7.00$6.72$6.7974.21K

Latest CV news

The latest Smart Investors Daily articles mentioning CV.

Stock researchCompany · Overview

CV research

Overview

Company profile and research snapshot.

Company profile

CapsoVision Inc is a commercial-stage medical technology enterprise, innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company's core technology platform is an orally ingestable capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. The Company's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D directed at the large intestines.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.00
Implied upside
—
Analysts
—
CV recent ratings
DateFirmRatingTarget
Mar 27, 2026BenchmarkSpeculative Buy—
Dec 31, 2025BenchmarkSpeculative Buy—
Jul 28, 2025BenchmarkSpeculative Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

CapsoVision to Participate in Upcoming Investor Conferences

SARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, plan to participate in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment Conf

Benzinga · Aug 13, 2026

CapsoVision Q2 2026 Earnings Call Transcript

CapsoVision (NASDAQ:CV) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By